These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23308105)

  • 1. Effect of aripiprazole on mismatch negativity (MMN) in schizophrenia.
    Zhou Z; Zhu H; Chen L
    PLoS One; 2013; 8(1):e52186. PubMed ID: 23308105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of quetiapine on cognitive function in schizophrenia: a mismatch negativity potentials study.
    Yuan GZ; Zhou ZH; Yao JJ
    Acta Neuropsychiatr; 2009 Feb; 21(1):26-33. PubMed ID: 25384526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state.
    Higuchi Y; Sumiyoshi T; Seo T; Miyanishi T; Kawasaki Y; Suzuki M
    PLoS One; 2013; 8(1):e54080. PubMed ID: 23349791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal associations between mismatch negativity and disability in early schizophrenia- and affective-spectrum disorders.
    Kaur M; Lagopoulos J; Lee RS; Ward PB; Naismith SL; Hickie IB; Hermens DF
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():161-9. PubMed ID: 23851120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Auditory Mismatch Negativity and P300a Elicited by the "Optimal" Multi-feature Paradigm in Early Schizophrenia.
    Fisher DJ; Campbell DJ; Abriel SC; Ells EML; Rudolph ED; Tibbo PG
    Clin EEG Neurosci; 2018 Jul; 49(4):238-247. PubMed ID: 29502452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study.
    Bervoets C; Morrens M; Vansteelandt K; Kok F; de Patoul A; Halkin V; Pitsi D; Constant E; Peuskens J; Sabbe B
    CNS Drugs; 2012 Nov; 26(11):975-82. PubMed ID: 23018547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
    Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
    J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of glycine on auditory mismatch negativity in schizophrenia.
    Greenwood LM; Leung S; Michie PT; Green A; Nathan PJ; Fitzgerald P; Johnston P; Solowij N; Kulkarni J; Croft RJ
    Schizophr Res; 2018 Jan; 191():61-69. PubMed ID: 28602646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials.
    Kane JM; Assunção-Talbott S; Eudicone JM; Pikalov A; Whitehead R; Crandall DT
    Schizophr Res; 2008 Oct; 105(1-3):208-15. PubMed ID: 18790605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data.
    Robb AS; Carson WH; Nyilas M; Ali M; Forbes RA; Iwamoto T; Assunção-Talbott S; Whitehead R; Pikalov A
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):33-8. PubMed ID: 20166794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
    Janicak PG; Glick ID; Marder SR; Crandall DT; McQuade RD; Marcus RN; Eudicone JM; Assunção-Talbott S
    J Clin Psychiatry; 2009 Jan; 70(1):25-35. PubMed ID: 19192472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia.
    Docherty JP; Baker RA; Eudicone J; Mathew S; Marcus RN; McQuade RD; Mankoski R
    Schizophr Res; 2010 Jul; 120(1-3):199-203. PubMed ID: 20547037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in the duration and frequency of deviant stimuli engender different mismatch negativity patterns in temporal lobe epilepsy.
    Hirose Y; Hara K; Miyajima M; Matsuda A; Maehara T; Hara M; Matsushima E; Ohta K; Matsuura M
    Epilepsy Behav; 2014 Feb; 31():136-42. PubMed ID: 24412859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trial of aripiprazole in the treatment of first-episode schizophrenia.
    Lee HY; Ham BJ; Kang RH; Paik JW; Hahn SW; Lee MS; Lee MS
    Psychiatry Clin Neurosci; 2010 Feb; 64(1):38-43. PubMed ID: 20416024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.
    Pigott TA; Carson WH; Saha AR; Torbeyns AF; Stock EG; Ingenito GG;
    J Clin Psychiatry; 2003 Sep; 64(9):1048-56. PubMed ID: 14628980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
    Findling RL; Robb A; Nyilas M; Forbes RA; Jin N; Ivanova S; Marcus R; McQuade RD; Iwamoto T; Carson WH
    Am J Psychiatry; 2008 Nov; 165(11):1432-41. PubMed ID: 18765484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients.
    Glick ID; Poyurovsky M; Ivanova O; Koran LM
    J Clin Psychiatry; 2008 Dec; 69(12):1856-9. PubMed ID: 19026264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
    Kwon JS; Jang JH; Kang DH; Yoo SY; Kim YK; Cho SJ;
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):73-81. PubMed ID: 19154213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.
    Kerwin R; Millet B; Herman E; Banki CM; Lublin H; Pans M; Hanssens L; L'Italien G; McQuade RD; Beuzen JN
    Eur Psychiatry; 2007 Oct; 22(7):433-43. PubMed ID: 17555947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.